[Skip to Content]
[Skip to Content Landing]
From JAMA's Daily News Site
June 19, 2013

Selections From News@JAMA and JAMA Forum

JAMA. 2013;309(23):2428. doi:10.1001/jama.2013.6971

The development of new antibiotics remains alarmingly neglected, according to an Infectious Diseases Society of America public policy article.

Only 2 new antibiotics, telavancin and ceftaroline fosamil, have been approved since 2009, the authors noted. They also said that the number of new antibiotics annually approved for sale in the United States has continued to dwindle and that the number of large multinational pharmaceutical companies actively developing antimicrobial drugs is still declining. The gravest concern, according to the report, is the absence of drug candidates to combat infections caused by gram-negative bacilli, which can cause significant morbidity and mortality.